92621 ⎘
Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
Sub-classes:COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING PRODUCTION OF TRIMETHYLAMINE
#2NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION
#3STYRYL CARBOXYLATE DERIVATIVES
#4STYRYL CARBOXYLATE DERIVATIVES
#5Method for producing triarylorganoborates
#6COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS
#7Styryl carboxylate derivatives
#8High penetration drugs and their compositions thereof for treatment of Parkinson diseases
#9ACTIVATORS OF CLASS I HISTONE DEACETYLASES (HDACS) AND USES THEREOF
#10Method for producing triarylorganoborates
#11SPECIFICALLY-SHAPED CRYSTAL OF COMPOUND AND METHOD FOR PRODUCING SAME
#12SPECIFICALLY-SHAPED CRYSTAL OF COMPOUND AND METHOD FOR PRODUCING SAME
#13ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER
#14Indanes as PD-L1 inhibitors
#15Method for producing triarylorganoborates
#16Activators of class I histone deacetylases (HDACs) and uses thereof
#17Lipids and lipid compositions for the delivery of active agents
#18High penetration drugs and their compositions thereof for treatment of Parkinson diseases
#19Method of producing epoxy compound and catalyst composition for epoxidation reaction
#20Activators of class I histone deacetlyases (HDACs) and uses thereof
#21Antimuscarinic compound having a low content of impurities
#22High penetration drugs and their compositions thereof for treatment of parkinson diseases
#23Quaternary ammonium salt compound, composition for forming a resist under layer film, and patterning process
#24Inhibitors targeting drug-resistant influenza A
#25Reference markers for fesoterodine fumarate
#26TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
#27Polymerizable liquid crystal compound, a liquid crystal composition comprising the compound, and an optically anisotropic body
#28NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE
#29Method for preparing high-purity fesoterodine fumarate
#30Lipids and lipid compositions for the delivery of active agents
#31Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods of preparing the same and use of the same
#32Process for preparing fesoterodine
#33Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methyl-benzoate hydrochloride, methods for preparing the same and use of the same
#34Analgesic compounds, methods, and formulations
#35Processes for the preparation of fesoterodine
#36Method for the prophylactic or therapeutic treatment of glucocorticoid-induced osteoporosis
#37Activators of class I histone deacetlyases (HDACS) and uses thereof
#38Compositions and methods for the treatment of giardiasis
#39Process for obtaining 3, 3-diphenylpropylamines
#40CRYSTALLINE FORMS OF FESOTERODINE FUMARATE AND FESOTERODINE BASE
#41Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof
#42Process for the preparation of fesoterodine or a salt thereof
#43Derivatives of 3,3-diphenylpropylamines
#44PROCESS FOR PREPARATION OF PHENOLIC MONOESTERS OF HYDROXYMETHYL PHENOLS
#45Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof
#46Prodrugs of oxazolidinone CETP inhibitors
#47Fesoterodine Substantially Free of Dehydroxy Impurity
#48Process for the preparation of fesoterodine with low impurities content
#49NOVEL MANDELATE SALT OF FESOTERODINE
#50Amorphous Fesoterodine Fumarate
#51Method for preparing fesoterodine and/or fesoterodine fumarate
#52Method for preparing high-purity fesoterodine fumarate
#53Shortened synthesis using paraformaldehyde or trioxane
#54Derivatives of 3,3-diphenylpropylamines
#55Dendritic nano-antioxidants
#56Accelerated synthesis of substituted hydroxymethyl phenols
#57Synthesis of phenolic esters of hydroxymethyl phenols
#58Solid forms of fesoterodine fumarate
#59Synthesis of substituted hydroxymethyl phenols
#60Process for the production of benzopyran-2-ol derivatives
#61Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof
#62Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof
#63Derivatives of 3,3-diphenylpropylamines
#64High purity bases of 3,3-diphenylpropylamino monoesters
#65Ibopamine maleate, method for preparing it and pharmaceutical compositions containing it
#66Process for making aminoalkylphenyl carbamates and intermediates therefor
#67Melanin concentrating hormone antagonist
#68Derivatives of 3,3-diphenylpropylamines
#69Highly pure bases of 3,3-dipheyl propylamine monoesters
#70Phenol derivative